<SEC-DOCUMENT>0001178913-13-000964.txt : 20130402
<SEC-HEADER>0001178913-13-000964.hdr.sgml : 20130402
<ACCEPTANCE-DATETIME>20130402070219
ACCESSION NUMBER:		0001178913-13-000964
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130402
FILED AS OF DATE:		20130402
DATE AS OF CHANGE:		20130402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		13733284

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1312897.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
    <title>zk1312897.htm</title>
    <!--Licensed to: Z_K_GLOBAL-->
    <!--Document Created using EDGARizer 2020 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt">Form</font> <font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 14pt">6-K</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of April 2013</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-30902</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">COMPUGEN LTD.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="90%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">72 Pinchas Rosen Street</font></div>
</td>
</tr><tr>
<td valign="bottom" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Tel-Aviv 69512, Israel</font></div>
</td>
</tr><tr>
<td valign="bottom" width="90%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices)&#160;</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form 20-F&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div>&#160;</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compugen Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On April 2, 2013, Compugen Ltd. (the &#8220;Company&#8221;) issued a press release announcing the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate (ADC) cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. A copy of the press release is filed as Exhibit 99.1 to this Form 6-K and incorporated by reference herein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information contained in this Report, including the exhibit hereto, is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form F-3, File Nos. 333-171655 and 333-185910.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Number</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Description of Exhibit</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Press Release dated April 2, 2013.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Signatures</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="bottom" width="48%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">COMPUGEN LTD.</font></div>
</td>
</tr><tr>
<td align="left" colspan="4" valign="middle" width="100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date: April 2, 2013&#160;</font></div>
</td>
<td align="left" valign="bottom" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;</font></div>
</td>
<td align="left" valign="bottom" width="36%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">/s/ </font><font style="DISPLAY: inline">Dikla Czaczkes Axselbrad</font><font id="TAB2" style="LETTER-SPACING: 3pt; COLOR: black">&#160;</font></font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dikla Czaczkes Axselbrad</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
<td valign="bottom" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>exhibit_99-1.htm</title>
    <!--Licensed to: Z_K_GLOBAL-->
    <!--Document Created using EDGARizer 2020 5.4.4.0-->
    <!--Copyright 1995 - 2013 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit 99.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><img src="compugen.jpg" alt=""><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For Immediate Release</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Compugen Discloses Focused Target Discovery Program for </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Antibody-Drug Conjugate Cancer Therapy</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Second program follows initial program that resulted in discovery of multiple novel </font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">immune checkpoint molecules and establishment of Pipeline Program</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Initial discoveries from new program anticipated before yearend</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel Aviv, Israel, - April 2, 2013 --- Compugen Ltd. (NASDAQ: CGEN) disclosed today the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate (ADC) cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Company's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody (mAb) drugs for cancer immunotherapy.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cancer therapy through ADCs, whereby the antibody delivers a cytotoxic drug directly and specifically to the cancer cell in order to induce direct killing of the cells, addresses an area of high unmet medical need and is of great interest to the pharma industry. However, the lack of suitable ADC targets is a major problem. This provides an opportunity for Compugen to serve as a key source of such potential targets and their mAbs.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. Anat Cohen-Dayag, president and CEO of Compugen, stated, &#8220;Concurrent with our further research and development activities and collaboration discussions involving our leading Pipeline Program product candidates, we are pleased to disclose this second focused discovery effort, which was a previously stated objective for 2013. Based on the success of our first such effort, we expect initial ADC target discoveries by yearend, thus further expanding the scope and diversity of the cancer therapy arm of our pipeline.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The new discovery platform is designed to provide hypothesis-driven analysis of complex sets of expression and clinical data to predict proteins that can serve as novel mAb targets. The platform is based on the integration of multiple proprietary systems, tools, and algorithms from Compugen&#8217;s existing predictive discovery infrastructure with additional new specialized algorithms and queries geared towards ADC target discovery. Through the use of this discovery platform, utilizing data from numerous clinically annotated biological samples from various solid cancers, Compugen intends to identify potential high value targets expressed on the surface of various types of cancer cells that are associated with poor clinical outcomes, such as low overall survival and short relapse-free survival.&#160;&#160;A planned additional use of the discovery platform is the identification of mAb targets associated with tumors unresponsive to certain treatments, thereby potentially providing a more personalized therapeutic approach based on the target's expression level in individual patients.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="3">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About ADC Cancer Therapy and Cancer Immunotherapy</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ADC cancer therapy destroys cancer cells through the use of an antibody or antibody fragment linked to a high-potency cytotoxic agent, called the payload.&#160;&#160;Unlike traditional cancer therapeutics, ADC therapy is designed to target and destroy only the cancer cells. The antibody specifically targets the cancer cell, where the payload is released and selectively kills the cancer cell. ADCs against a number of targets, both in solid and hematologic tumors, have already demonstrated clinical success, with two ADC products gaining FDA approval in the past two years.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cancer immunotherapy, such as that based on immune checkpoint blockade, is designed to stimulate the patient&#8217;s own immune system to mount durable anti-tumor immunity and tumor destruction, and does not rely on toxic agents to destroy the cancer.&#160;&#160;Clinical studies employing mAb blockade of immune checkpoints have shown unprecedented durable therapeutic responses that offer a possible cure of metastatic disease. Antibodies targeting immune checkpoints have been termed &#8220;the next frontier" in the treatment of cancer, with the first such product receiving FDA approval in 2011.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ADC cancer therapy and cancer immunotherapy are both considered major breakthroughs in treating cancer, and for both, the identification of appropriate targets is critical and has proven very difficult using traditional discovery approaches.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Compugen</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology.&#160; The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the&#160;<font style="FONT-STYLE: italic; DISPLAY: inline">in silico</font>&#160;(by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.cgen.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which include statements related to Compugen&#8217;s potential to serve as a key source of targets for ADC cancer therapy and Compugen&#8217;s expectation regarding initial&#160;&#160;ADC target discoveries&#160;&#160;by yearend, include words such as &#8220;may,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;potential,&#8221; &#8220;believes,&#8221; and &#8220;intends,&#8221; and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks and other factors are discussed in the "Risk Factors" section of Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen&#8217;s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Company contact:</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tsipi Haitovsky</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Global Media Liaison</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compugen Ltd.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Email: tsipih@netvision.net.il</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Tel: +972-52-598-9892</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugen.jpg
<TEXT>
begin 644 compugen.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`&L!``,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`*`"@`H`0G`H`H76NZ-:W#P7&K6$,L9PT<EPBLI]P
M3Q5*$FKI`1_\))X?_P"@YIG_`(%1_P"-/V4^S`/^$D\/_P#0<TS_`,"H_P#&
MCV4^S`JZQXW\&Z19F[U7Q;H5A;@X,UU?Q1IGTRS`54,/5F[1BW\@-FQN;>\L
MXKNTFCF@G021RQME74C(((Z@BLFK.P$M`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$5U,(;=Y=COL4MLC7+-@=`.YI;@>5:E
M\5?%LC3VR?`OQM/;MN0/YEO&77IG'F97(_&O2C@:>C]M'\?\A'FMQX7\#SSO
M/<?L;7\TLK%WEE@LV=V/4DF3))]37I1KXB*M'%V7J_\`(FR[#/\`A$O`(_YL
MPNA_VZV7_P`73^LXG_H,_&0:=C'\9>%]$.ANG@_]C?3$U-B`DFKPVOD1CN2L
M;[F/L"OUK6CB*O-^^Q;MY-W_`!#;9'3?LQ?"`:K<7&M_$?X)?#CPZEI*GV"W
ML-'*W#NI#>:6:9U"@XP,9)R>,<\V99BX6AAZ\Y7WN]/0<;]3Z810@PHP!7SY
M0M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`8'Q
M`\;>$O`^F0:CXO\`$.GZ):7,OD137LPC5Y,%MHSU.%)_"M:.'JUI<M*+;\@/
M!/%/C#X?ZUXAN]33]KZ]TN.X<LECIUS91P6Z]E0&(G`]6))[FO;HX:O3@H_5
M;^;YO\R?F4/[<\`?]'HZ]_X'6/\`\9K3V5?_`*`U]TO\Q?,/[<\`?]'HZ[_X
M'6/_`,9I^RK_`/0&ONE_F'S/./&?Q,\$ZC'J'AZ_^,'QKUG36<PO);P6`@NT
M!ZJ3M8H?<#(]C7?1P-56J*C33\W*Z_&Q+DC`^'GA#X(^-_'&F>$=+UOXM+=:
MO-Y*M)#8QH@P2Q+*Q*C`/(!(K?$XC&8>FZLHPLO\0HI-VU/T%T6PL]*TFUTS
M3[:.VM+*);>"",86.-0%50/0``5\))N3YI;FVQ:H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`/2@#@?BBGQ-EUV"/PCX4\#:OI
MJ0AC+X@U&>"9)22&"HEO(-NW;SG)R>..>O#>P2;JRDGY+_@H3OT.:^R_'3_H
MFOPB_P#!S=?_`"%73S83_GY/[E_\D+W@^R_'3_HFWPB_\'-U_P#(5'-A/^?D
M_N7_`,D'O&'\2+/X]_\`"#:B]OH'PC\*M"BS-K(U69Q:1HP:1B)+$K@HK*2>
M@;/:MJ$L$JBYI3EY66O_`),+WCR#^T/C=_T7'X*_^#2#_P"0:];V6#_Y\U/N
M?_R1/O\`D=!\*O$GQ*T3XA:7JGC#XQ_""]T&WD)O8+35H1*8RI!*8LT.1UQN
M&<=:Y\70P\Z3C1HU%+I=:?FQKF3U/KFSGAN;6.XMI4EAF4/')&P974C(((Z@
MBOE[6T9H2T`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`<Y\2_!6B>.="CTG7/MR0PS+/')8WDMK*C@$</&P.""00>#GZ5M0Q$
MZ$N:'XI/\PL>#>/O"/PJ\(>)'T;4=$^--W(B+(MQI<FJ7D$BGNLD3,/J#@CT
MKV:%?$UH\T907KRI_B0TD8OD?!K_`*%GX_?^`>MUM;%_S4_O@+0;+:_!:2)X
MI?"OQ[DCD4J\<ECK3*RD8((/!!'8TU]<6JG3^^`:'"^.O#GPPLKR`>#O@-X_
MUFV=/WOVVQU.TDB8'C&8B&!'H<BNVC5Q4D_:UXQ]'%_J)I=$8?\`8^@C_FU_
MQG_WWJ/_`,9K?FJK_F*C_P"2_P"8M/Y3U7X(?&+Q!X"L[3PW#\"O']MX<2;Y
MOW%[=R6:'KY2O$/E!YV`],X["O+QF6PK-U/;Q<O5*_XE*36ECZSL+B.ZLXKF
M$L8YD612R%3@C(R#@CZ'FOF;6=C0FH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`K:M%=2:9<16%R+:Y>-EBF9-XC<CY6*]\'
M'%-63NPN>*B7XWQ_)-\9/ADLB?*X_LUAAAUX\[CFO7_V+_GU/[_^`(//^-?_
M`$67X9?^"YO_`(]1_L7_`#ZG]_\`P`#S_C7_`-%E^&7_`(+F_P#CU'^Q?\^I
M_?\`\`#PKXMZ-K_A?Q0W_"0?M-W5C-JI>\2VTJ;4YH(P6Y"[)VV#).%)X'3B
MO9PE2E4A:EAKI=^6_P"*,Y:=3EQJ!_Z.I\0?]^]8_P#CE=7*MOJJ_P#)?\B;
MK^8^J/V%]2>_^$NI0-\09_&RZ?K$L"ZC<0SI)$&BAE\IC,2[X,I8'.`'"C[M
M?,YQ!0KZ4^2Z6FGZ&L=M#VBO**"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`,#XC:Y?^'_``XU[I?AC4?$5T9%C6PL&17(/5BS
MD``#W]*UH4XU)\LI**[L-CY]F\(^#I9GFE_8TE>21B[NZ6)+$G))._DYKWE7
MK15HXS3UD3\AO_"&^"_^C,&_[]V/_P`73^LU_P#H,_&0QDOA+P-"FZ;]C58E
MZ;I!8*/S+T_K%?IC/QD!POB/POXO'B"[;PI^S-\.[#1V8?9H+ZW@DG"@#)=D
MN%7).>`.!CDUV4Z]+D7ML3-R\F[?*Z);ET12_P"$7^*3$)'^SI\,7=ONHE@A
M+'T`%U5>WPJU^L3^]_Y"][L?7_P.\*+X.^&VGZ3)I&B:7?.OVB^@T2V,%K]H
M?ERBEF/H,DG./PKY7%U_;57*[:Z7U=C0ZZN8`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`Z4;`<C\0OBA\/O`MU%;>+O%^E:1-.,I%<S
M`.1Z[1R!]:Z*&#KXC^%%L+I'#>-/CO\`"+6-$>PTGXWZ7H$TA&Z^LQ'),B^B
M"5&0'IR5;^H[J>4XN$KRHM^7_#"YD>>#Q/\`#8#_`)/-\6_^!-C_`/(E=WU;
M$_\`0)'[I?\`R1%O,/\`A)_AM_T>;XM_\";'_P"1*/JV)_Z!(_=+_P"2#YG&
M>*/B]X7TO57M--^.7QHUN*/@W=G'IRQ,?]DO;@L/?&*ZZ.759J\J-./D^;_Y
M(3=NIQWCOQI\./&L<$7BWQK\:]8BM26BBNFTTHC'N%$0&??&:Z\/A<3A[NE"
MFG_V]^K%==V7_A#\'OAQ\2=66U\,:?\`%EK8-MFU*XCTR.V@]<N8N3[+DU&+
MS'$82/[QT[]O>O\`F-03V/J3]G_]GCP%\)]2GU?2Q>ZMK$V574M5,;201_W(
MA&B*@/<XW'N<8`^;QV;5\8E&5E%=%_P6V7&*B>MUYA04`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`A(%`'%_$K4/BG;ZI!#X!\-^%=0M/
M+W37&M:O-;-OR?E5(X).``#DGOC'&:Z</'#M-UI->B3_`#:$[]#D9F^/LMPT
M\WPY^%$DKX#2/KET6..F2;.NI?4EHIS^Y?\`R0O>&_\`%^O^B;_";_P=W7_R
M'1?!?SS^Y?\`R0>\8/CCQI\2_!T=N?%>@_`_0C>[UMCJ/B.XB$I4#=MS:#=C
M<N<>H]:WH8>A7=J3J.V]HK_,/>/&;[Q)\5KJ\DN#^T+\(;<R,6\FUUB*.)/9
M5^RD@#W)/J2>:]F-#"Q5OJ]3YI__`"1+OW+'AMOC9X@UN#1M`^._PUU34;G)
MBM+/5HY)'P,G"BSST!J:GU*C'FJ4)I>:?_R0*_1GT%\"_AAXZTGR]5^)OCN3
M7+W!QI5I#$EG$3W9Q&KRGZ[5Y^Z<`UX.-QE&?NX:'*N[>O\`DBXIVU/6K6V@
MMH1%;PQQ(O(6-0H_(5YCUW&2CB@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`1NG%)@?)_B"+X-/XAU%[SPA\;FN6O)FF:"'4S&9#(
MVXIM?;MSG&.,8QQ7TE*>*4$HSIVMUY;_`(DZ%3R/@E_T)WQT_P"_.J__`!=:
M<^+_`)Z?WP#0/(^"7_0G?'3_`+\ZK_\`%T<^+_GI_?`-#B_B78^$+C5[5?"W
MP3^(?B*RBA):;7+C589(9&;YE12&^4A4.0>2/:NO#3JI-U:T(ORY61*VUC`M
MM!@N+J&V@_9GU\RW$BQ1A]3U)%+,0HRQ0!1DCDG`K>5?E3?UE?='_,5E_*?9
MWP(^$WA+X;:0\NBZ%;V.J7\:?;I4N)+@[@.4223YM@.<#C/7%?)8S'U<4_WC
MNEMT_!&J26QC?'']H?P!\,]3.BWDMYJ^MJ`7TW2T5V@!&0978A$[<9+8.0I%
M;8+*<1BES15H]WH$I*)YC9?MKZ,UV%NOA]J:6X.&:"_BDD`]E(49^K#ZUZ4N
M&JJ6DU^)'M$?0/PH\>>'?B)X'MO%7AF[>:RG)1TF3RY;>1?OQR*?NLIZ]0>"
M"003X6(PU3#5'2J*S1HFF>4_%']K/X=^%M:GT?0[;4/%%U:DI+/8;$M$<'!3
MSG/SD>J*R]LY!%>GALAQ-:*G*T4^^_W$N:1SF@?MI^&);Y$USP3K.GVC'#7%
MI.ET4']XIA20/]G)]`:Z)\-UDO<FF^VQ*J(]N\8?$SPQH7P:G^)L=P^J:%%:
MK=Q26&TM<HQ`4)N*C))`P2*\:CA*E2NL/:TKVU+NDKGE&@?MA_#[4]=L]-D\
M/>)-/2ZE$;WEZMJD-NO\4CD3$A5&2<`GC@$UZE3A_$0@Y\R?DK_Y$JHC)U;]
MM/PO%K+1Z7X(UN]TU7P+N6:."61<_>6)LD9Z@,5/J%/36'#=9QO*:3["]HC>
M^('[6_P]T/2].FT&TU#Q!>:C;)=&UA"PBT5OX)G;(63((VJ&(QS@$$X8?(,1
M4DU)J*6GKZ>0W-+8Z;]F[X]Z!\7+R^TJWTF\T?5[",3O:7#K(DD1.W<CKUP>
M""`1D=:YLPRNI@DI-W3Z^8XR3.0\0?MA^`=*\0ZEI!\,>*KIM-O)[)I[>.V,
M<IBD:,NF9@2I*$@D#((KKH\/8BI",^9*ZOKY_(7.BGXJ_;+\&V1MDT#PMK&K
M.\*2W!EDCMT@=E#&+/S%W4DJQ`VY'#-SBZ7#M>=^>2B)U$MCT_X"?&;PS\4_
M"M_JNE0W5A<Z.0+^PNPOF0`J2K@J2&1@K;6']U@0""!YN.R^K@YJ$];[,J,D
MU='F,_[:?P^C\S;X0\7R",L`5BM?GP<<9G[UZ2X;Q#^U'[W_`)"]HCM?C'^T
M/X8^&RZ"NMZ!K]Q/KUB+](+1("UNAQ\LFZ11NR2.,C@\UQ8/*JN*YN1I<KMK
M_P`,-R2+OP!^.GAWXLW>L1:+HFM:9'HD44L\^IK"J'>7X!21N0$R<XX(J<=E
ME3!<O.T[]F.,D]CS_P`<?MD>"=-UA[3PKH.H^)+>)BIU!95MK>7WB+`LZ_[6
MT`]02.:[J'#U><5*HU&_3J2ZB6Q(_P"V7\/8]*L;@^'/$TES<*_VBUAB@)M6
M4@`%FD4,&SE2N>`<[2,4EP[B>9KF6GGO^'02J(]*^`WQ@T/XJ:!JFM:5I6J:
M39:3*(99-4$2!CLWD@H[#`&,DD5Y^-R^>#FH2:;?8M-,\Y^(7[87P_T35)K#
MPWI>I>)?L[%6O82MO:,1P=CO\SC/\07:1R&->AA^'L14CS3:CY:W^Y$NHEL0
M>`?VQO!FK:[;Z?XD\/:EX>ANI%B2^,J7$$9/`\PKAE!.!D*0,\X'-.OP]7IQ
M<H24K=-F$9INQZ3^T%\:/#GPBL](GUO3]3U$ZU)(D$6FK$S!44,SG>ZC;\RC
M@GEA7GX'+JF,<E3:5NY4I*)P>C?MA?#>\L]1NKK1O$FG)I\"RHD\,#27<C-M
M6&)4E)+GDDG"J`2S`<UVU.'\3!Q2:=_P\WH)31F^$/VR/#&J>++/2]6\(:II
M-E>W"6ZW_P!H281%V"JTB``A<D9*EL=<$9K2KP]6A3<XS3:5[>A*J*]CZ67I
M7SYH+0!Y)\21X^T[Q;<-#\:_"WARPNV,EG8:GIL1E1``&^9I5+@-GG'<"O1H
M/#N%I4G)]T_^`)W,'^T?'O\`T<EX!_\`!=;_`/QZMO\`9_\`GQ+[W_D+7N']
MH^/?^CDO`/\`X+K?_P"/4?[/_P`^)?>_\@U[G"?'FPUC4?#T.N^)?VEK)8-%
MWX7PO$T<S"5HU.Z."XS(`57'!*@L>A-=V!J4XSY*6'U?\VVGJM!-/N6_V'M+
MTO4_B5J6MV'Q<\5^+UT:S$;66HI=PPQ/,Q"N1+(RN=L;@#'&<^E3G,Y1I1A*
MBH7=[JW3T007F>^_''Q6?`WPA\2>+8U#3:1ITUQ!&>DDP4B-3]7*C\:\3!T/
M;UX4N[2*;LC\U]!TW4O%?C2RTE[R674_$6HQP2WA.9'EFD`>3GOR3^`K]$J3
MCAZ3DEI%;',E=ZGUM^T/\`_A[JVNZ1::/XQ\+>!(])L1;-8ND2R3C/RN^75F
M.`1N;)/.2:^3P&:UJ:DYQ<[NYM*%SB?B'H[_``1_9?U71?#WCJW\0#QOJZV_
MVS3\*D4:Q8F4%6;YB$`//3BNS#S688V,YPMR+9_@*W)$\O\`V5/!%EX[^.>B
M^'M1MQ)I<(>[O(1PKQ1KD(<=BQ4''K7JYKB98?#2G%ZZ)$4XZZE#]H:VT.Q^
M.OBNQ\-645EI5I?F"WMX?N(415?;[&0.?QJ\M<WA8.H[NWZZ"DM6=SXHUB[T
MO_@G_P"%O#\DA'_"1>))F2)CS]DA>28L/]GSDB'_``,>M<-*G&>:3FOLQ_%V
M7Y7*?P&#^R+X(TGQ]\<+72?$%H+K1["RGU&\MRQ42*FU5!(YQOD0X]JWS;$S
MPN'YJ;M)NR_,5-)O4\WU6YL)M0OKS3(_+T^2>:6T3.[;`78QC/?Y-M>E34N5
M*>^E_4E^1ZE^TAX*\.>!/"/P\TW3]/6'7=1TDZAJMSO8F9FVXR"<#!+`8`X%
M>7EN)J8BI5G)^ZG9%SBDE8Z?]@P+HEWX]^(,VU8O#NAL$9NF\[I/Y(!7-GKY
M_9X=;M_\`JFK:G@-M!>7IAM+7#7U](D$.[D&61@JY_X$PS7O7C!7Z+]#+<]O
M_;?\#>#?AWK/@KP[X5T^.UN_[,GEU*0.6><AH4B>3)ZDB?!&.C>V/&R3$UL1
M&I.J[JZM^-_T+J*UBA^S)J]WX8^&/Q>\3VS*/LN@PVL8+8W3RO*L8_G3S2"J
MUJ%)]9/[M`@[)L\V^&VAMKOCSP_X<B`;[??V]K@]P74'/X9KT\35]E2G4?1,
MF.YZ9^W=K::K^T;J%E`P-OH5I!8(`>`0N]A^!?'X5YN1T>3"*3ZMLJIN,T:_
MN/"'[$NI/:2-#=?$'7C8R.G!-I%'^\&?1@FP^SFE."K9BD]J<;_,<;J&AS_[
M+?@BS^(/QST;P[JD32:6GF7E[$I(\V*,9$9(Y`9BH..V1WKIS3%2PV&E.&CV
M1--)LK?M(6'A_2OCSXITGPK8QV6E6%VMM%;Q$[4=8T$F,_\`33?59;*<L+"5
M1W;%/?0['7]5OO"?[#7A?0;626VE\?:E=ZA=E3C?:I(50`C^%T2$GV)%<=.G
M&MF4ZC^PDEZV_1W+=XPL>?\`PBOKO2/%G]LVGP_;QG]BC(^Q-8374,+M]UW6
M)6]&P&X//I7?C(J=/D=3DOUNE?[R87WL0^,-#\6ZQK>I:I!\,_$6F1WTKS+8
MV>@7@A@W<[$!CX7T%.E5HTXJ+JIVZN2_S#E=[V/0OVUM4O9O&?A'PW>2L[>'
M/#-M'*C@ADN)OFE!S_L1P?K7GY+32IU*J^U+\%_PXZNZ*GPG\&>&)?V9/B3\
M1O$VG_:KC3(QIVCLSLHBN7"JC#'4F66)><]#6F+Q558RCAZ3M?5_UZ!&*Y;L
M\_\`ASH[^(/B/X;T"/KJ6JVMN3_LF5=Y_P"^0U=^*J*G0G-]$R(J[2/U+7I7
MYJ=0M`''_&'PEX<\0>'WU#5OAWHWC.^TR-GLK'4+>%F9CC*H\H(3./H<"NG#
M8BK1E:G4<$][-_H#/&AX:T[_`*,KT3\]+_PKU_;S_P"@Q_\`DQ.O87_A&M._
MZ,KT3\]+_P`*7UB?_08__)PN^PJ>&[!&#+^Q;HJD="K:6"/TH]O/_H,?_DPM
M>QT'[)6A^-]$\3>)!XF^&WA[PCI]TL+63Z3:6\$DVUY/DF,1(8JK#!Z<MCK7
M/F=2C.,/9U')K>[;^ZXXJW0])^-O@Y/'_P`*/$'@YI_LS:O9/!%.1D12]8W(
M[@.%)'?%<&$Q#PU:-9=&4UI8^!C\//C!\.?'=CJ?_""ZP=1T:[2YM[BSLVN[
M=W4\$&/.5/O@\U]O]<P>*I./.DFMF[,YU!QU1LM\*/C9\9?B'=^(=:\,7%G=
MZFZ^=J.L0?9H($`VJ%0_/M4#A0.>>><UE''X/`4E3IRNET75^H<LI.[/H3XR
M?LZK<?LSZ)X#\%21F_\`"TGVN!IP(Q?2MN\XMCA6<NQ'8'`KP,%F[CBY5Z^T
MM'Y=ON-91TLCYE\(:)\;?AGXQ;4M#\&^)M.U4PO;&1-+:Y0HW7E0R]@0<\$"
MOI:U7!8NGRSFFO6QDE*.QT'PE_9N^)?C?7DN/$>GWGAW2YI3)=WVHX%S)DY;
M9'G.XY/+8`Z^U<V*SC#X>/+2?,TK*VPU3;>IWW[;'PZ\67VL^#O"OP_\"ZK>
M^'O"VDM!";*)3'&SLHVY+#D+$F?K7%DN,I152K7FE*3Z_/\`S+G'30J?LS_#
MWXA^"OAA\4_$5SX/U>UU^^TI-,T>R:-1.[E9"73#8QNECSR/]559EC,/7KT:
M:FN5.[?3I_D*$6DSR?PK\"_BA<Z_H^DWGP^UVQL+B]MK6>YDB39;P-*B22'#
M=%0LWX5ZE?-,-&$I1J)NSMZVT(4'<](_;*\"_$OQ?^T%J.H:'X"UR]TFRM+>
MRM9X(T,;A5+,5RPXR^.G\-<&3XO#4,*HSFDVVV7.+>PL6BZ[\,/V%O%">(-(
MN])U?Q7J\=B+>Y`5UCRHR<$\%4D_.I=2&+S*'LW>,4%N6.IXA\/-!\1>(_&%
MIIGA."276$)NK58W"L&B^<%2>,\#&>M>WB:M.E3<JNW^>AE%.^AUWB'PI\<?
MB9X_>^USPEXDO]:G5(&FO+(VT,*+D!0Q`15!)/&>23R37'3Q&"PE/EIS2COH
M[LMQDV>_>*/@!K7AG]C+4_!OAY1J?B6]O8=7U%83C[7(K)F*//94C4*#U*YZ
ML:\.GFL*N81K5-(I67EY_>S3EM&R/GSX6?#?XPOX_P!/D\,>$M>TG5;*X$D>
MH7MF88K5A_$S2#:1@G@;L]*][%8W!^Q:J333Z)ZLRC%WT#Q-\)/C1=^(M3O;
M[P+XCU2[GN9'FOC$G^E-N/[SENC8!'MBG1S'!1A%1FHJVVN@W"5]3W_Q_P#`
MZ^UC]D?P;X9MYK&P\4Z#&M^MM>2+%YK2`^="2?NM\PYZ;D&?4?/T,U5/'5*L
MM82T_P`F6X^[8\>^&7P8^/-AXL2Z\-6DWARY3,,FJIJ$(2&-OO9*ELC'.,9X
MXP>:]C$9G@)T[5'S>5B(PDCQQVDO$=K&>2[ENW/D3L69KAG;Y7)/)+$AN>>>
M>:]=6@O>5DOP\B=V?:?[4WP-UO7?@AX,TWP?;+<WW@FSCM%T_<%,\(B1"$)X
MW#8#@]>:^.RS,X4L3.=9Z3=[]G>YM.-T>!_"R[^._P`,GUK3O"G@KQ%:3:W&
MD5R9-%ED9"FX*R/C:&&]N<D<^U>YBHX#%<LJLU[M^IG%2BK(]+_9N^$GQRUO
MQC8ZQX]\8^/-%T*RD6>2TN_$EX9[T@Y";!,0JYQG/;@#FO.S',,'"FX4(1<G
MUY59?@7%2W9Q/[17P]^*WBSXY>)]?M/AYXAN;2XO"EO,L28>)`$4C+="%XKN
MR[&86AAH0=1)_P"9,XML[+Q5\._'^E_L-^'/`^E>$]7NM6UC6/[1U6QAC4O`
M@=YE63YL<2+#CD_=KAHXRA+,I5I22BE9/Y6_S&XM1L9'['/PB\=Z?^T-HVM>
M*?!^J:1IVCP7%V)[R-0CR[/*1!ACS^]9A_N5OF^84)85TZ,TV[;??^@H1:>I
M]OKT%?&HV8M,`([4`)M%+E2'<,#WHL@N&![T607`#%%A"TP$P/>E8=PP*+"%
MQQBG:P"8^HI6``,4]@`CBE8`VCWHL`;1[TPV`J/<4K`>&_ML?#7QQ\3=$T'2
M?"45DT%E<R7-R;JX\O)V[4`&.>I->QDV-HX2<IU;[6T(G&ZLCD?V//@%XT^'
MWQ6N/$WB^+3T@BT]X+7[+<^8WFNRYR,=-H-=F;9M1Q-%4Z5]];BA#E/J#;]:
M^;L:+0,4P#;]:`#;]:5@/G_]M3X":C\5Y])U_P`/36/]JZ5"]LUK?#"3Q%@P
MVO@[6!SUX(/;'/N9/FBP7-3J7Y7V)G&^QX%HO[.GQ\TBPU#2='TU],L=73R;
M^"RU988;M,$;954C>N"00>H)!X)%>[/-\#-J<W=K:ZO8S49H]8_9K_98O/#G
MC"R\6_$"]M+B?2Y1/9Z5:9>,2C[LDCG[VWJ%`QD`YX%>5F.>*M3=&@K)[ME0
MIVU9]2X`KYNQH&*+`M```HL`;?<T6`,"BP`%QZT6`6GL`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
